BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Prognosis
58 results:

  • 1. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
    Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
    Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Splenic B-cell lymphoma/leukemia with prominent nucleoli: A three-case series of the newly named old entity and review of literature.
    Rai V; Saha A; Gondha S; Manimaran P; Sawhney J
    J Cancer Res Ther; 2024 Jan; 20(1):315-320. PubMed ID: 38554340
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x
    Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
    Troussard X; Maître E; Paillassa J
    Am J Hematol; 2024 Apr; 99(4):679-696. PubMed ID: 38440808
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. BCL-X
    Jenkins LJ; Luk IY; Chionh F; Tan T; Needham K; Ayton J; Reehorst CM; Vukelic N; Sieber OM; Mouradov D; Gibbs P; Williams DS; Tebbutt NC; Desai J; Hollande F; Dhillon AS; Lee EF; Merino D; Fairlie WD; Mariadason JM
    Cell Death Dis; 2024 Mar; 15(3):183. PubMed ID: 38429301
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis.
    Chang L; Lang M; Lin H; Cai H; Duan MH; Zhou DB; Cao XX
    Leukemia; 2024 Apr; 38(4):803-809. PubMed ID: 38388646
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Clinical and molecular study of radiation-induced gliomas.
    Trkova K; Sumerauer D; Bubenikova A; Krskova L; Vicha A; Koblizek M; Zamecnik J; Jurasek B; Kyncl M; Malinova B; Ondrova B; Jones DTW; Sill M; Strnadova M; Stolova L; Misove A; Benes V; Zapotocky M
    Sci Rep; 2024 Feb; 14(1):3118. PubMed ID: 38326438
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy.
    Zhou Q; Zhang J; Zhang J; Liang S; Cai D; Xiao H; Zhu Y; Xiang W; Rodrigues-Lima F; Chi J; Guidez F; Wang L
    Biol Direct; 2024 Jan; 19(1):6. PubMed ID: 38178263
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. IκB kinase-α coordinates BRD4 and JAK/STAT signaling to subvert DNA damage-based anticancer therapy.
    Pecharromán I; Solé L; Álvarez-Villanueva D; Lobo-Jarne T; Alonso-Marañón J; Bertran J; Guillén Y; Montoto Á; Martínez-Iniesta M; García-Hernández V; Giménez G; Salazar R; Santos C; Garrido M; Borràs E; Sabidó E; Bonfill-Teixidor E; Iurlaro R; Seoane J; Villanueva A; Iglesias M; Bigas A; Espinosa L
    EMBO J; 2023 Nov; 42(21):e114719. PubMed ID: 37737566
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Hairy Cell leukemia: Where Are We in 2023?
    Mendez-Hernandez A; Moturi K; Hanson V; Andritsos LA
    Curr Oncol Rep; 2023 Aug; 25(8):833-840. PubMed ID: 37097545
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. [Clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant].
    Wei C; Jin XX; Cai H; Wang X; Zhuang JL; Zhou DB
    Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):416-421. PubMed ID: 37032137
    [No Abstract]    [Full Text] [Related]  

  • 12. High-grade desmoplastic infantile astrocytoma in a 1-year-old child with Down's syndrome: a case report.
    Habib MH; Alavi MZ; Goraya A; Zaman S; Ahmed A
    J Med Case Rep; 2022 Nov; 16(1):427. PubMed ID: 36333774
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. A Novel Identified Necroptosis-Related Risk Signature for prognosis Prediction and Immune Infiltration Indication in Acute Myeloid leukemia Patients.
    Sun Y; Wang R; Xie S; Wang Y; Liu H
    Genes (Basel); 2022 Oct; 13(10):. PubMed ID: 36292722
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. TLS/FUS-ERG fusion gene in acute leukemia and myelodysplastic syndrome evolved to acute leukemia: report of six cases and a literature review.
    Zhang H; Zhan Q; Wang X; Gao F; Yu J; Wang J; Fu W; Wang P; Wei X; Zhang L
    Ann Hematol; 2022 Dec; 101(12):2583-2600. PubMed ID: 36181538
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Mast cell leukemia with novel braf variant and concomitant atypical KIT variant.
    Chen T; Malysz J; Washburn E; Songdej N; Zhang Y; Bayerl M
    Cancer Genet; 2022 Aug; 266-267():33-36. PubMed ID: 35717863
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.
    Pérez-Carretero C; Hernández-Sánchez M; González T; Quijada-Álamo M; Martín-Izquierdo M; Santos-Mínguez S; Miguel-García C; Vidal MJ; García-De-Coca A; Galende J; Pardal E; Aguilar C; Vargas-Pabón M; Dávila J; Gascón-Y-Marín I; Hernández-Rivas JÁ; Benito R; Hernández-Rivas JM; Rodríguez-Vicente AE
    Am J Hematol; 2022 Jul; 97(7):903-914. PubMed ID: 35472012
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.
    Troussard X; Maître E; Cornet E
    Am J Hematol; 2022 Feb; 97(2):226-236. PubMed ID: 34710243
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [Hairy cell leukemia: What are the best treatment options for relapsed or refractory patients?].
    Troussard X; Maitre E; Paillassa J
    Bull Cancer; 2021; 108(7-8):771-778. PubMed ID: 34023063
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and braf in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21).
    Burlet B; Ramla S; Fournier C; Abrey-Recalde MJ; Sauter C; Chrétien ML; Rossi C; Duffourd Y; Ragot S; Buriller C; Tournier B; Chapusot C; Nadal N; Racine J; Guy J; Bailly F; Martin L; Casasnovas O; Bastie JN; Caillot D; Albuisson J; Broccardo C; Thieblemont C; Delva L; Maynadié M; Aucagne R; Callanan MB
    Cold Spring Harb Mol Case Stud; 2021 Feb; 7(1):. PubMed ID: 33608382
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Loss of FBXW7-mediated degradation of braf elicits resistance to BET inhibitors in adult T cell leukemia cells.
    Yeh CH; Bellon M; Wang F; Zhang H; Fu L; Nicot C
    Mol Cancer; 2020 Sep; 19(1):139. PubMed ID: 32907612
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.